cancer related symptoms and/or chemotherapy or radiation therapy related symptoms (e.g. chemotherapy-induced nausea and vomiting, pain, sleep problems, appetite loss)
Conditions
Interventions
Group 1: Patients with cancer related and/or chemotherapy or radiation therapy related symptoms are regularly asked about symptoms, concomitant medication use, and quality of life.
Sponsors
Stiftung Swiss Tumor Institute
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Written informed consent; - Adult male and female patients > 18 years suffering from cancer related and/or chemotherapy or radiation therapy related symptoms; - Patients who have not been previously treated with a medical cannabis product for cancer related and/or chemotherapy or radiation therapy related symptoms but now are scheduled for a treatment with cannabinoids; - Using the consilium careTM App on their personal smartphone (Android or iOS system) as part of the routine medical data assessment; - No cognitive impairment as judged by the treating physician; - Ability to read and answer questions in German.
Exclusion criteria
Exclusion criteria: Patients who are in the opinion of the investigator unsuitable for participation in the registry for any other reason not listed in the inclusion and exclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To get insights from therapy with CBD:THC products added to SoC for supportive and palliative treatment of cancer related and/or chemotherapy or radiation therapy related symptoms in daily clinical practice under real world conditions. | — |
Secondary
| Measure | Time frame |
|---|---|
| Developing a data pool for future research questions. Capturing patient data continuously during medical cannabis-treatment to get insights on: - treatment pathways, - duration of medical cannabis treatment, - proportion of chemotherapy patients for whom guideline-compliant treatment of CINV is insufficient, - proportion of patients suffering from further cancer related and/or chemotherapy or radiation therapy related symptoms, - proportion of cancer patients receiving cannabis in total and per center, - proportion of patients for whom cannabis results in relief of their symptoms, - reasons for withdrawal from medical cannabis therapy, - information on related symptoms, e.g., appetite loss, anxiety, pain and sleep problems, - change in concomitant medications, - development of quality of life, - data on optimal dose titration. | — |
Countries
Switzerland
Contacts
Public ContactAndreas Trojan
Onkologie See-Spital Horgen
Outcome results
None listed